• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K filed by Capstone Holding Corp.

    4/15/26 6:28:32 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email

    Unavailable

    Get the next $CAPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schultz Edward Christopher

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:42:32 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lipman Matthew E.

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:41:21 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Toporek Michael

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:40:16 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capstone Announces Investor FAQ Focused on 2026 Guidance and Earnings

    Company invites shareholder submissions; FAQ to expand on growth trajectory, margin profile, and path to profitability Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, will publish an investor FAQ during the week of May 4, addressing key questions from its shareholder base. The FAQ will provide additional detail on the Company's recent earnings and 2026 guidance, which includes 54% revenue growth and approximately 4x EBITDA growth. Ahead of publication, Capstone is inviting shareholders to submit questions by emailing [email protected]. Submissions will be reviewed by the Company's leadership team, with a selection of response

    4/21/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Reports FY2025 Results and Guides to 54% Revenue Growth and 4x EBITDA Growth in 2026

    FY2025 gross margin expands to 23% on $46.9M revenue; FY2026 guidance calls for $72.1M of revenue, ~$18.7M of gross profit (+73%), and a positive EBITDA run-rate starting in Q2 Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. The Company closed FY2025 with ~$46.9 million in revenue and gross margin expanding to 23.0%, reflecting acquisition-driven scale and a higher-margin product mix. For FY2026, Capstone expects revenue to rise 54% to $72.1 million, gross margin to reach 26%, and EBITDA to increase more than fourfold to approximatel

    4/16/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Awarded Eldorado Stone Distribution, Targeting $5 Million in Organic Revenue Growth

    $5 million in organic revenue sold through existing distribution channels with no incremental investment; share-of-wallet capture from existing customers accelerates near-term revenue ramp Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced it has been awarded distribution rights for Eldorado Stone, a premium manufactured stone veneer brand from Westlake Royal Building Products. The Company expects the addition will contribute $5 million in annualized run-rate revenue by Q3 2027, sold entirely through Capstone's existing distribution channels with no incremental infrastructure investment. Capstone is already a top-three national

    4/6/26 7:30:00 AM ET
    $CAPS
    $WLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials

    $CAPS
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 5:15:36 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 4:10:39 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    4/16/26 3:09:28 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care